SCHEMBL3522964

SCHEMBL3522964

CC(=O)c1ccc(-c2cc(N)ccc2F)s1.Nc1ccc(F)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.43
HSD17B1 P14061 12/20 0.39
HSD17B2 P37059 12/20 0.39
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
GABRA4 P48169 1/20 0.38
GABRE P78334 1/20 0.38
GABRA6 Q16445 1/20 0.38
GABRG1 Q8N1C3 1/20 0.38
GABRG3 Q99928 1/20 0.38
GABRQ Q9UN88 1/20 0.38
ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3988281 0.92 ERN1 (0.49) ERN1HSD17B1HSD17B2ALDH1A1KDM4E
SCHEMBL3522968 0.78 ALDH1A1 (0.39) ALDH1A1KDM4EGAAMAPTESR1
SCHEMBL7808468 0.78 LMNA (0.45) ERN1HSD17B1HSD17B2ALDH1A1KDM4E
SCHEMBL6136853 0.76 KDM4E (0.44) ERN1HSD17B1HSD17B2ALDH1A1KDM4E
SCHEMBL5704931 0.75 MAPT (0.45) ERN1HSD17B1HSD17B2ALDH1A1KDM4E
SCHEMBL3531252 0.74 INPPL1 (0.38) KDM4EMAPTHPGDMCHR1
Hydrochloric Acid SCHEMBL5704978 0.74 MAPT (0.44) ERN1HSD17B1HSD17B2ALDH1A1KDM4E
SCHEMBL27760166 0.73 ESRRG (0.44) ERN1HSD17B1HSD17B2ALDH1A1KDM4E
Fluoromethane SCHEMBL28294738 0.70 CYP3A4 (0.54) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL9602 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759366-B2 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2010-07-20 US disclosed
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use GPR119, GIPR, LIPC ERN1 3526/4885HSD17B1 670/4885HSD17B2 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.